nav arrow

CogWellin™ and Traumatic Brain Injury/Chronic Traumatic Encephalopathy (TBI/CTE)

CogWellin™ targets the right patients at the right time.

I was first to find that acetylated Tau in the brains of AD patients matches the same acetylated Tau in the brains of 3 deceased TBI/CTE patients, This was done in collaboration with the Department of Neurosurgery in West Virginia Medical Center, Morgantown, W. Va.

An article published in 2017 by the Armed Forces University Hospital in Bethesda, MD, has shown that in the animal model of TBI, immediate release salsalate reduces levels of tau, reduces markers of inflammation, increases the production of the brains neuroprotective hormones called thyrotropic releasing hormone (TSH) as well as oxytocin.

Keeping sustained, safe and therapeutic levels of salicylic acid in the blood and brain of those who sustained head trauma using immediate release salsalate is impossible. This is why CogWellin’s provisional patented, unique once daily dosing at 200 and 400 mg should result in sustained and therapeutic as well as safe levels of salicylic acid in the blood and brain of TBI patients, ultimately reducing the future likelihood of life threatening CTE.

Biomarker for AD and TBI/CTE

I have been working on a spinal fluid test to confirm presence and amount of acetylated Tau in AD patients. In the past six months, I have been developing the best model to confirm the presence and amount of acetylated tau in the spinal fluid of approximately 30 well characterized and longitudinally followed AD subjects. I am comparing their results to approximately 30 non AD patients (healthy volunteers of similar ages).

Working now with the world's leading testing company called EMD Millipore, a division of Merck in Germany, we expect to have results in about 6 weeks. If confirmed as a valid biomarker for AD and TBI, it will be a very often used test before and after treatment for AD as well as before and after head trauma.

Home salicylic level monitoring for AD and TBI patients

As I have seen in my now 36 years of medical practice, no two patients taking the same drug at the same time at the same dose will have the same level of that medication in their blood. As such, CogWellin is working on developing the first of its kind, home blood monitoring of salicylic acid. It will have results done in minutes from one small drop of blood taken from one's finger as is done for blood sugar testing. These results will be sent to the prescribing doctor immediately via an APP. IF the results are in the "ideal" zone to keep inflammation in check, the patient will be instructed to keep the daily dose unchanged. If the level is below the ideal zone, the patient will be instructed to increase as judged appropriate by the doctor. This testing will provide personalized dosage monitoring, improving the results of the medication.

cogwellin and Traumatic Brain Injury/Chronic Traumatic Encephalopathy